Integra LifeSciences
IART
236 hedge funds and large institutions have $2.88B invested in Integra LifeSciences in 2017 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 95 increasing their positions, 73 reducing their positions, and 23 closing their positions.
87% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 23
30% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 73
6% more funds holding
Funds holding: 223 → 236 (+13)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $2.96B → $2.88B (-$86M)
66% less call options, than puts
Call options by funds: $653K | Put options by funds: $1.92M
94.42% less ownership
Funds ownership: 185.69% → 91.27% (-94%)
Top Buyers
| 1 |
BlackRock
New York
|
+$318M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$47.9M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$46.3M |
| 4 |
Millennium Management
New York
|
+$32.5M |
| 5 |
Jennison Associates
New York
|
+$26.5M |
Top Sellers
IART Hedge Fund Activity: Q1 2017 in Review
236 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2017, worth a combined $2.88B — down 2.9% from $2.96B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new IART positions and 23 closed out — a net gain of 20 holders — while 95 added to existing stakes and 73 trimmed.
The largest buyer was BlackRock, adding an estimated $318M. The largest seller was Fidelity Investments, cutting an estimated $126M.
- 236 institutional investors held Integra LifeSciences (IART) as of Q1 2017, up from 223 in Q4 2016.
- Funds reported $2.88B of Integra LifeSciences stock for Q1 2017, down 2.9% quarter-over-quarter.
- 43 funds opened new Integra LifeSciences positions in Q1 2017 and 23 closed out, a net change of +20 holders.
- The largest Integra LifeSciences buyer in Q1 2017 was BlackRock, an estimated $318M added.
- The largest Integra LifeSciences seller in Q1 2017 was Fidelity Investments, an estimated $126M sold.
Based on aggregated 13F filings for Q1 2017.